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Abstract
Purpose Our objectives were to assess the quality of PET
images and coregistered anatomic images obtained with
PET/MR, to evaluate the detection of focal uptake and SUV,
and to compare these findings with those of PET/CT in
patients with head and neck tumours.
Methods The study group comprised 32 consecutive patients
withmalignant head and neck tumours who underwent whole-
body 18F-FDG PET/MR and PET/CT. PET images were
reconstructed using the attenuation correction sequence for
PET/MR and CT for PET/CT. Two experienced observers
evaluated the anonymized data. They evaluated image and
fusion quality, lesion conspicuity, anatomic location, number
and size of categorized (benign versus assumed malignant)
lesions with focal uptake. Region of interest (ROI) analysis
was performed to determine SUVs of lesions and organs for
both modalities. Statistical analysis considered data clustering
due to multiple lesions per patient.
Results PET/MR coregistration and image fusion was feasible
in all patients. The analysis included 66 malignant lesions
(tumours, metastatic lymph nodes and distant metastases),
136 benign lesions and 470 organ ROIs. There was no statis-
tically significant difference between PET/MR and PET/CT
regarding rating scores for image quality, fusion quality, lesion
conspicuity or anatomic location, number of detected lesions
and number of patients with and without malignant lesions. A
high correlation was observed for SUVmean and SUVmax
measured on PET/MR and PET/CT for malignant lesions,
benign lesions and organs (ρ =0.787 to 0.877, p <0.001).
SUVmean and SUVmax measured on PET/MR were signifi-
cantly lower than on PET/CT for malignant tumours, meta-
static neck nodes, benign lesions, bone marrow, and liver
(p <0.05). The main factor affecting the difference between
SUVs in malignant lesions was tumour size (p <0.01).
Conclusion In patients with head and neck tumours, PET/MR
showed equivalent performance to PET/CT in terms of qual-
itative results. Comparison of SUVs revealed an excellent
correlation for measurements on both modalities, but under-
estimation of SUVs measured on PET/MR as compared to
PET/CT.
Keywords PET/MR . PET/CT . Hybrid imaging .
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Introduction
Staging and treatment planning of malignant head and neck
tumours require endoscopy with biopsy and additional MRI,
CT and/or whole-body 18F-FDG PET/CT. Due to its excellent
soft-tissue contrast,MRI is widely used as the first-line approach
to imaging head and neck tumours [1, 2]. Since the introduction
of 3-T scanners and new coil technology, high-resolution MRI
of the head and neck area has become possible in clinical routine
with improved results for the staging of primary tumours and for
the detection of recurrent disease [1, 2]. However, in the staging
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of nodal disease, 18F-FDG-PET/CT has been shown to be
superior to conventional anatomicMRI sequences [3], and there
is general agreement that PET/CT is indicated whenever distant
metastases or second synchronous tumours are suspected [3].
Since the diagnostic information of MRI and PET are comple-
mentary, combining the two modalities should facilitate tumour
detection and staging. The use of MRI instead of CT for
attenuation correction also reduces radiation dose, especially in
patients undergoing repeat PET studies [4].
Recently introduced PET/MR systems include new tech-
nologic features that allow acquisition ofMRI and PET data in
the same patient during a single examination providing high-
quality fusion ofMRI and PET images [5–16]. In the so-called
simultaneous PET/MR systems, PET inserts are installed in-
side the bore of the MRI machine [5], whereas in the so-called
sequential PET/MR systems the patient is transferred between
the MRI and the PET scanner while remaining on the same
table support [6, 16].
The purpose of this prospective study was to assess the
feasibility of sequential PET/MR and of PET/MR image
fusion, and to compare its performance to that of PET/CT
with respect to lesion detection, characterization and anatomic
localization of focal uptake in patients with malignant head
and neck tumours. In addition, our objective was to compare
18F-FDG uptake quantification with PET/MR and PET/CT
despite different PET characteristics, data acquisition and
processing protocols.
Materials and methods
Study design and patient selection
This prospective clinical study was approved by the institu-
tional ethics committee and was performed in accordance with
the guidelines of the Helsinki II declaration. Over a period of
12 months, we included consecutive patients with head and
neck tumours in whomMRI of the head and neck and whole-
body 18F-FDG PET/CT were clinically indicated and who
gave informed consent to participate in the study. Exclusion
criteria were standard contraindications for MRI and refusal to
participate in the study. None of the patients potentially eligi-
ble for the study refused to participate and all patients were
able to sustain both examinations. Therefore, 32 consecutive
patients (13 women, 19 men; mean age 59±18 years) with
known or suspected head and neck tumours underwent a
whole-body PET/MR scan followed by a whole-body
PET/CT scan. In 13 patients, the indication for imaging was
primary staging of head and neck squamous cell carcinoma
(12 patients) or lymphoma (1 patient). In 18 patients, the
indication was suspected recurrence of head and neck
squamous cell carcinoma (17 patients) or rhabdomyosarcoma
(1 patient). In one patient, the indication was head and neck
lymph node metastasis from an unknown primary. The proof
of diagnosis consisted of histology (endoscopic biopsy or
surgical resection), follow-up ≥12 months or a combination
of histology and follow-up. Histologic proof with or without
follow-up was available for the primary site in 28 patients, for
lymph node status in 18 patients, and for the chest and the
remainder of the body in 4 patients. Follow-up alone was the
proof of diagnosis in 4 patients for the primary site, in 14
patients for lymph node status, and in 28 patients for the
remainder of the body, respectively.
Imaging protocol
All patients received a single 18F-FDG injection, followed by
a PET/MR scan and a subsequent PET/CT scan. 18F-FDG
(373±28 MBq) was injected in the PET/MR system and the
time for radiotracer uptake was used for the diagnostic MRI
scan of the head and neck and for total body MRI sequences
for attenuation correction and anatomic localization. Awhole-
body PET acquisition was obtained on the PET/MR system,
after which the patient was transferred to the PET/CT scanner.
This approach did not require additional injection of 18F-FDG.
PET/MR acquisition
All PET/MR scans were performed on a Philips Ingenuity
time-of-flight (TF) PET/MR scanner (Philips Healthcare,
Cleveland, OH), which is a sequential PET/MR system
consisting of a GEMINI TF PET scanner and an Achieva
3-T TX MRI scanner with a common rotating table plat-
form in between [6, 16]. After radiotracer injection, a
dedicated MRI scan of the head and neck was performed
using a SENSE neurovascular coil. The voxel size of the
T1-weighted (TR/TE 683/16) and T2-weighted (TR/TE 3,
528/90) sequences was 0.45×0.45×3 mm, the voxel size
of the diffusion-weighted (TR/TE 3,867/260) sequence
was 1.3×1.3×3 mm, and the voxel size of the STIR
(TR/TE/TI 5,043/80/200) sequence was 0.45×0.45×
4 mm. The dedicated head and neck MRI scan (total
acquisition time 40 min) was followed by a whole-body
Dixon and MRI attenuation correction sequence using a
quadrature body coil. The whole-body Dixon sequence
acquired after injection of gadoterate meglumine (Dotarem,
0.1 mmol/kg; Guerbet, Aulnay-sous-Bois, France) had the
following parameters: flip angle 10°, TE1 1.1 ms, TE2
2.0 ms, TR 3.2 ms, 450×354 mm transverse FOV, voxel size
0.85×0.85×3 mm, total acquisition time 2 min 17 s. This
sequence [13, 14, 17] provides four datasets (in-phase and
opposed-phase gradient echo images, and derived water-only
and fat-only images), among which we prefer the water-only
images for anatomic localization and PET/MR data fusion
because of their excellent anatomic detail and lesion conspi-
cuity. The MRI-based attenuation correction procedure has
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recently been described [18]. This fast multistack whole-body
MRI sequence called atMR, is acquired in 2 min 29 s. It
consists of a 3-D multistack spoiled T1-weighted gradient
echo sequence with the following parameters: flip angle 10°,
TE 2.3 ms, TR 4.1 ms, smallest water–fat shift, 600 mm
transverse FOV with a slab thickness of 120 mm, voxel size
1.9×1.9×6 mm. After the atMR acquisition, the table was
rotated and the PET scan was performed. PET acquisition was
started 85±20 min after injection. It included a total of ten bed
positions for a total PET acquisition time of 32 min.
PET/CT acquisition
PET/CT data were acquired on a Biograph 64 True Point
scanner (Siemens Healthcare, Erlangen, Germany). The CT
scan for attenuation correction and diagnostic purposes had
the following parameters: 120 kVp, 180 mAs, collimation
24×1.5, pitch 1.2, 1 s per rotation. The slice thickness of the
reconstructed CT images was 2 mm and the reconstruction
interval was 1.5 mm. No intravenous or oral contrast material
was administered. PET data acquisition was started 146.2±
20 min after injection of 18F-FDG with a total of eight or nine
bed positions resulting in an acquisition time of 24 – 27 min.
The delay between the two PET acquisitions was 61±20 min
and the delay between the end of the PET acquisition on the
PET/MR machine and the start of the PET acquisition on the
PET/CT machine was on average 29 min. This time lag
resulted from the necessity to transport the patient from
the PET/MR to the PET/CT unit and to place the patient
as similarly as possible to the positioning on the PET/MR
table.
Image reconstruction
On the PET/MR system, the MR map obtained by three-class
segmentation (air, soft-tissue, lungs) of the corresponding
atMR sequence was used to correct the PET images for
attenuation. A pre-generated template taking into account
table and RF coil attenuation was added to the patient atten-
uation map. The PET images were reconstructed using a 3-D
line-of-response (LOR)/TF/blob-based ordered subsets expec-
tation maximization (OSEM) algorithm and standard param-
eters recommended by the manufacturer (three iterations, 33
subsets, voxel size 4×4×4 mm).
On the PET/CT scanner, CT-based PET images were
reconstructed using an attenuation-weighted, ordered subset-
expectation maximization (AWOSEM) iterative reconstruc-
tion algorithm (four iterations, eight subsets, voxel size
4×4×5 mm). Therefore, a similar voxel size was available for
comparison of the PET data from the two modalities.
The standardized uptake values (SUV) for all PET data
were calculated according to the standard formula [19].
Image evaluation and SUV measurement
Prior to image evaluation, PET/MR and PET/CT DICOM
datasets were anonymized. For each PET/MR examination
the whole-body PET, the water-only Dixon and the atMR
sequences were available for review. For each PET/CT acqui-
sition, the PETand the unenhanced CT images were analysed.
In order to make sure that identical anatomic regions with
respect to craniocaudal extent were covered by the two exam-
inations, the images of either modality were truncated so as to
cover exactly the same anatomic area explored by the two
modalities.
Two physicians with 6 and 16 years of experience reading
PET and head and neck MR images evaluated all datasets in
consensus. They were blinded to clinical, endoscopic and
histopathologic results. In a first session, they evaluated all
PET/MR images in a predefined random order and 2 weeks
later all the PET/CT images in a different predefined order.
The aim of having a gap between the two readings, rating the
images in different orders and anonymizing the data was to
minimize the effect of memory on lesion detection and
characterization.
All images were evaluated on a PACS workstation using
OsiriX software (OsiriX v. 4.0, 64 bits; Geneva, Switzerland).
For PET/MR, all areas of focal uptake were first identified on
axial PET images, after which the atMR and water-only Dixon
sequences were used for PET/MR image fusion and to iden-
tify the anatomic lesions corresponding to focal uptake. In
analogy, for PET/CT, focal uptake was first identified on axial
PET images, after which the CT data were used for anatomic
correlation. The readers equally evaluated maximum intensity
projections of PET images and performed 2-D reconstructions
in any other plane whenever necessary.
Analysis of PET/MR and PET/CT data included qualitative
and quantitative assessment. Using a three-point scale (poor–
moderate–good), the two readers evaluated image quality
based on the presence of geometric distortion and breathing
or swallowing artifacts, and they assessed areas of focal up-
take with respect to alignment between PET and anatomic
structures, quality of fusion, lesion conspicuity and anatomic
location. Lesions with focal uptake were defined as well-
circumscribed areas of increased tracer uptake relative to the
surrounding structures. The two readers classified areas of
focal uptake either as probably malignant or as probably
benign based on visual analysis, asymmetry of tracer uptake
and taking into consideration the normal distribution of
18F-FDG in the head and neck region. For the differentiation
of malignant from benign focal uptake in the head and neck, a
SUV threshold of 3 was used. This threshold was chosen in
accordance with the literature [20, 21] and based on our
clinical experience. Fusion of PET images with anatomic
images from the contrast-enhanced Dixon sequence was used
for morphologic correlation. The number of lesions was
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recorded. Malignant lesions with focal uptake were further
categorized as tumour (T), lymph node metastasis (N) or
distant metastasis (M) according to UICC/AJCC recommen-
dations [1]. Benign uptake included inflammatory lesions
(such as reactive lymph nodes, sialadenitis, oesophagitis, ar-
teriosclerotic plaques), posttraumatic lesions and physiologic
uptake (due to muscle activity or brown fat). The two readers
tagged all lesions with focal uptake on the computer screen
during the blinded evaluations using different symbols for
benign and malignant focal uptake. Tagging was done at the
level of the size of the largest lesion. After evaluation and
tagging by the two readers, a third physician with 8 years
experience in head and neck MRI and PET identified all
tagged lesions on both modalities and identified those lesions
that were detected on one modality but were missed on the
other modality. Discrepant readings were recorded. Then the
two readers who had initially rated the PET/MR and PET/CT
images reevaluated the discrepant readings to determine
whether the lesions missed initially on one modality could
be detected retrospectively.
SUVs of all tagged areas of focal uptake were then mea-
sured using predefined regions of interest (ROIs) for size and
shape saved in DICOM format. The measurements were done
on anatomically corresponding PET/MR and PET/CT images
of the same patient allowing comparison of SUVs at the same
level. Predefined ROIs were also used for measuring SUVs of
the liver, lungs, spleen, bone, muscle, salivary glands and
background. To ensure that ROIs were placed on the anatomic
area to be measured, images were reviewed visually slice-by-
slice on the computer screen, as reported by previous investi-
gators [22]. For all ROIs, SUVmean and SUVmax were mea-
sured. Lesion size was additionally measured according to
RECIST criteria.
Statistical analysis
Fisher’s exact test was used to compare the number of lesions
with focal uptake detected by PET/MR and PET/CT. The
Wilcoxon signed-ranks test was used to compare the scores
obtained with the two modalities for image quality, fusion
quality, anatomic location and conspicuity of focal uptake.
Spearman’s rank correlation coefficient (ρ ) was calculated to
assess the correlation between SUV measured on PET/MR
and those measured on PET/CT [23]. Concordance between
the SUVs from PET/MR and PET/CT (SUVmean and SUVmax)
was determined according to the methods of Bland and Alt-
man [23, 24]. The limits of agreement were derived from
logarithmically transformed values to give limits for the ratio
of the actual measurements. Linear mixed models with a
random effect on patients for non-normally distributed sam-
ples of clustered data were used to calculate the relative
difference between SUVs from PET/MR and those from
PET/CT accounting for clustering due to multiple lesions per
patient [25, 26]. Linear mixed models were also applied to
explore the factors influencing SUVs in malignant lesions and
the difference between SUVs from PET/MR and those from
PET/CT. The explored factors were lesion size, anatomic
region (neck versus chest) and lesion type (malignant tumour,
metastatic lymph node, distant metastasis).
Statistical analysis was carried out using a freeware pro-
gram (R version 2.15.1; The R Foundation for Statistical
Computing, Boston, MA). Values of p <0.05 were considered
statistically significant.
Results
Image quality, fusion quality, lesion conspicuity and anatomic
location
PET/MR and PET/CT examinations were successfully
performed in all patients. Image quality, fusion quality, con-
spicuity and anatomic location of focal uptake were good
(Fig. 1). There was no statistically significant difference be-
tween mean PET/MR and PET/CT rating scores (Table 1) and
there was no mismatch in anatomic location between modal-
ities for any of the lesions with focal uptake. Breathing,
swallowing and motion had no major impact on image quality
in 31 patients and degraded image quality in one patient on
both PET/MR and PET/CTscans. Dental fillings and implants
impaired image quality on PET/MR scans in two patients
(6.25%) and on PET/CTscans in four patients (12.5%; Figs. 2
and 3).
Characteristics of lesions with focal uptake
Based on all available information from the PET/CT and
PET/MR datasets, 202 lesions with focal uptake were
detected: 66malignant and 136 benign. The number of lesions
with focal uptake varied from zero to 18 lesions per patient
with a mean of 7 lesions (benign and malignant) per patient.
The anatomic distribution of lesions, presumed lesion type
and lesion size are shown in Table 2. The number and char-
acteristics of benign lesions with focal uptake are given in
Table 3 and an example is shown in Fig. 4. The majority of
benign lesions with focal uptake were of inflammatory origin
(104 of 136; Table 2).
Concordant and discordant PET/MR and PET/CT readings
In the patient-based analysis, among the 32 patients included
in the study, 28 rated positive for malignant focal uptake on
PET/CT were also rated positive on PET/MR and 4 patients
rated negative on PET/CT were also rated negative on
PET/MR. Based on the final diagnosis, in the lesion-based
analysis, there were 32 head and neck tumours (25 patients
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with one head and neck tumour each, 2 patients with two
synchronous tumours, and 1 patient with three synchronous
tumours), 23 lymph node metastases and 11 distant metasta-
ses. Among the malignant lesions with focal uptake identified
on PET/CT there were 32 head and neck tumours, 21 lymph
node metastases (10 in the neck and 11 in the chest) and 9
distant metastases. On PET/MR, there were 31 malignant
tumours, 22 lymph node metastases (9 in the neck and 13 in
the chest) and 9 distant metastases.
Of the total 202 lesions, a discordant rating was present in 8
(3.9 %) in six patients (18.75 %). In six of the discordant
ratings, the lesion was either missed on PET/MR or on PET/CT
(on PET/MR four lesions seen on PET/CT were missed, and
two lesions not seen on PET/CTwere detected) and in two the
interpretation (benign/malignant) was discordant (Table 4;
Fig. 5). The final diagnosis in these eight lesions with a discor-
dant rating was based on histology alone or histology and
follow-up in six lesions. In two lesions, the definitive diagnosis
was established by follow-up of ≥12 months (Table 4). All
eight lesions with discordant ratings had morphologic corre-
lates on CTand on the Dixon sequence and were not caused by
artefacts. The lesions missed initially on one modality were
identified by the readers retrospectively, the conspicuity of the
respective lesion being poor on the modality on which the
lesion was initially missed.
Fig. 1 Comparable image
quality, fusion quality, lesion
conspicuity and anatomic location
by PET/CT and PET/MR in a
50-year-old woman with
squamous cell carcinoma of the
larynx T3N1M0. a Fused PET
and CT image, b fused PET and
water-only Dixon MR image, c
PET image from PET/CT, d PET
image from PET/MR, e fused
whole-body PETand CT image, f
fused PET and water-only Dixon
MR image. Distant metastases are
absent (arrows left glottic
tumour)
Table 1 Visual rating scores (1 – 3: poor–moderate–good)
PET/MR PET/CT p value
Image quality 2.95±0.25 2.96±0.2 0.18
Fusion quality 2.95±0.29 2.93±0.25 0.62
Lesion conspicuity 2.97±0.22 2.97±0.22 1
Anatomic location 2.95±0.22 2.96±0.2 0.16
p >0.05, nonsignificant
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SUVs measured on PET/CT and PET/MR
SUVs were measured on PET/MR and PET/CT for the 202
lesions with focal uptake, for organs (lung, muscle, bone
marrow, salivary glands, spleen and liver; 470 ROIs) and
background (32; Tables 5 and 6). For malignant tumours,
metastatic lymph nodes in the neck, benign lesions, bone
marrow and liver, SUVmean and SUVmax from PET/MR were
significantly lower than those from PET/CT. SUVmax from
PET/MRwere also significantly lower than the corresponding
values from PET/CT for the spleen and background. For all
other lesions (metastatic mediastinal lymph nodes and distant
metastases) and for all other organs (muscle, lung, salivary
glands) there was no statistically significant difference in
SUVs between the modalities.
Correlation and concordance analysis of SUVs
Spearman’s correlation analysis of tracer uptake between
PET/MR and PET/CT demonstrated a strong correlation for
malignant uptake (SUVmean ρ =0.877, n =66, p <0.001;
SUVmax ρ =0.873, n =66, p <0.001), benign lesions
(SUVmean ρ =0.817, n =136, p <0.001; SUVmax ρ =0.787,
n =136, p <0.001) and organs (SUVmean ρ =0.868; n =470;
Fig. 2 Degraded PET/MR image
quality due to dental implants in a
50-year-old woman with
recurrent squamous cell
carcinoma T3N0M0 of the oral
cavity. Moderate PET/MR image
quality (score 2) and good PET/
CT quality (score 3). Fused image
quality, lesion conspicuity and
anatomic location were
comparable by both modalities
(score 3). a CT image, b water-
only Dixon image, c fused PET
and CT image, d fused PET and
water-only Dixon MR image, e
PET image from PET/CT, f PET
image from PET/MR. Note the
comparable visualization and
anatomic localization of the
tumour (long arrows) along the
right horizontal branch of the
mandible (short arrows , dental
artefact)
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p <0.001; SUVmax ρ =0.872; n =470; p <0.001), as shown in
Figs. 6 and 7. Bland-Altman concordance analysis for
SUVmean and SUVmax from PET/MR and PET/CT (Figs. 6
and 7) showed a systematic bias (average difference) of 3 % to
19 % of the average SUVs between organs and lesions with
focal uptake. The systematic underestimation of SUVs from
PET/MR compared to those from PET/CTwas proportional to
average SUVs. This effect was more pronounced for focal
uptake than for organs. For average SUVmean >10 and
SUVmax >12, the relative difference in measurements was
substantial (Fig. 7). Average SUVmean >10 and SUVmax >12
were found in tumours with a mean size of 3.1 cm and 3.0 cm,
respectively, whereas SUVmean ≤10 and SUVmax ≤12 were
both seen in tumours with a mean size of 1.86 cm (p =0.007
and p =0.009).
Factors influencing SUVs of malignant lesions
Among the tested factors (lesion size, lesion type and anatom-
ic location), lesion size (≥1 cm) and lesion type were signif-
icantly correlated with SUV from PET/MR and from PET/CT
(p =0.003). The influence of the anatomic region was weaker
Fig. 3 Degraded PET/CT image
quality due to dental fillings in a
73-year-old man with radiation
therapy for a squamous cell
carcinoma T3N2M0 of the oral
cavity. a CT image, b water-only
Dixon sequence image, c fused
PET and CT image, d fused PET
and water-only Dixon MR image,
e PET image from PET/CT, f
PET image from PET/MR. The
PET/CT image quality is poor
(score 1), but the PET/MR image
quality is good (score 3). A lesion
with focal uptake cannot be
excluded on the PET/CT images.
PET/MR data were interpreted as
negative for focal uptake. The
quality of PET/CT and PET/MR
image fusion was comparable
(score 3), (arrows dental
artefacts)
468 Eur J Nucl Med Mol Imaging (2014) 41:462–475
on PET/MR (p =0.03) and was nonsignificant on PET/CT
(p >0.05). There were significant correlations between lesion
size and both SUVmean and SUVmax from PET/MR and from
PET/CT (ρ values 0.55 to 0.75, p <0.001).
Factors influencing the difference between SUVs measured
on PET/MR and those measured on PET/CT in malignant
lesions
Anatomic region and lesion type were not associated with
differences between SUVs from PET/CT and those from
PET/MR (p >0.05). In contrast, the size of the malignant
lesion was significantly associated with differences between
SUVs from PET/MR and those from PET/CT (SUVmean and
SUVmax, p <0.01). For malignant lesions <1 cm, the SUVmean
and SUVmax mean ratios for PET/MR and PET/CTwere 0.97
[0.81;1.34] and 0.89 [0.72;1.15], respectively. For malignant
lesions ≥1 cm, the SUVmean and SUVmax mean ratios for
PET/MR and PET/CT were 0.81 [0.70;1.00] and 0.77
[0.67;0.98], respectively.
Discussion
Coregistration of PET and MR images has recently become
available in the form of integrated (“simultaneous”) or dual
(“sequential”) technical solutions, thus combining two pow-
erful imaging modalities that are often complementary, espe-
cially in the field of head and neck oncology. PET/MR there-
fore holds promise to add diagnostic value or facilitate image
interpretation in a variety of clinical settings. Several research
groups have reported their initial observations with PET/MR
coregistration on simultaneous PET/MR systems for image
acquisition in patient series with a mixed spectrum of neo-
plastic and inflammatory pathologies in different body re-
gions, and the results have been favourable [12, 27].
Besides the issue of correlation between anatomic
coregistration obtained with PET/MR and PET/CT, the ques-
tion arises as to whether PET/MR and PET/CT provide com-
parable quantification of 18F-FDG uptake in terms of SUVs,
given that the conditions for attenuation correction may differ
between the two modalities and between one body region and
another.
Imaging head and neck tumours is generally challenging
owing to artefacts originating from breathing and swallowing,
dental implants, screws and plates that may degrade image
quality [11, 14, 28]. All patients included in the current study
were able to sustain both examinations. Only a small propor-
tion of PET/MR and PET/CT images were slightly degraded
and comparable scores were obtained with the two modalities
for image and fusion quality, lesion conspicuity and anatomic
location of focal 18F-FDG uptake. No statistically significant
differences were found between PET/MR and PET/CT for the
number of detected foci in the lesion-based and patient-based
analyses indicating that coregistration with a sequential
PET/MR system is consistently feasible with good results in
patients with head and neck tumours and that PET/MR and
PET/CT have a similar performance for lesion detection irre-
spective of location, lesion category, type of malignant lesion
or lesion size. Discordant readings in the current series were a
result of nonvisualization of a lesion on either PET/MR or
PET/CT or by discrepant categorization of a lesion seen on
both modalities. The lesions missed initially on one
modality were, however, identified by the two readers during
retrospective evaluation.
Table 2 Anatomic dis-
tribution, type and size of










Head and neck 139 (68.8)
Lesion type
Malignant tumour 32 (15.8)
Malignant lymph node 23 (11.5)
Metastasis 11 (5.4)




Table 3 Number and
characteristics of benign




Reactive lymph nodes 60
Radiation-induced mucositis 19
Sialadenitis 8
Benign bone fracture 7
Oesophagitis 4
Atheromatous plaques 2
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Fig. 4 Concordant evaluation for
malignant and benign lesions with
focal uptake by PET/CT and
PET/MR in a 65-year-old man
with squamous cell carcinoma of
the larynx T3N0M0. a CT image,
b water-only Dixon sequence
image, c fused PET/CT image, d
fused PET/Dixon MR image, e
PET image from PET/CT, f
PET image from PET/MR. A
left-sided supraglottic tumour
(arrows) has invaded the
preepiglottic space. Note the




Table 4 Discordant ratings for lesions with focal uptake on PET/MR and PET/CT
Region Type Location Detected on Diagnosis on Final diagnosis Sizea SUV PET/MR SUV PET/CT





No Yes Benign Malignant Inflammation 1.12 3.26 2.76 3.99 2.67
Neck Lymph node Level IB No Yes Benign Malignant Inflammatory node 1.39 2.13 1.67 2.98 2.14
Chest Lymph node Hilum Yes No Malignant Benign Inflammatory node 0.62 6.02 3.98 2.05 1.35
Chest Lymph node Hilum Yes No Malignant Benign Inflammatory node 0.62 5.27 3.33 2.50 1.85
Chest Metastasis Lung Yes Yes Malignant Benign Benign nodule 0.50 1.05 0.70 0.61 0.40
Chest Metastasis Bone No Yes Benign Malignant Bone metastasis 2.05 1.38 1.18 2.65 1.74
Chest Metastasis Lung No Yes Benign Malignant Inflammatory nodule 0.48 1.51 1.21 1.80 1.31
Chest Metastasis Pleura Yes Yes Malignant Benign Pachypleuritis 1.44 6.44 5.00 4.68 3.59
aMaximum lesion length in centimetres
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To the best of our knowledge, the accuracy of the quanti-
tative PET information derived from sequential PET/MR in
patients with head and neck tumours and the specific factors
that may influence these data has not yet been determined by
means of prospective quantitative analysis. PET scanner per-
formance, data acquisition, attenuation correction method and
tracer kinetics may vary among studies and may all contribute
to divergent SUVs among modalities and study protocols.
The limitations of the current study comprise technical
issues related to the two PET subsystems employed, the
number of iterations, and the time lag between the two PET
acquisitions. Technical differences between the two PET
subsystems included detector design (barrel vs. pixelated
Anger-logic detector), data acquisition (TF versus non-TF),
and reconstruction strategies (listmode 3-D LOR–TF blob-
based OSEM versus FORE+2-D AW-OSEM). We did not
attempt to match the number of iterations between the two
PET datasets, as matching the number of iterations will not
produce images with the same quality or quantitative potential
rendering evaluation of data more questionable given the
differences in data sampling between the two scanners and
the optimal choice of the number of subsets and subiterations.
The purpose of the current study was not to validate PET/MR
quantification but rather to evaluate the quantitative aspects of
Fig. 5 Discordant evaluations by
PET/CT and PET/MR in a
69-year-old man with
histologically proven recurrent
squamous cell carcinoma of the
nasal cavity T2N0M0. a , c Fused
PET and CT image; b , d fused
PET and water-only Dixon MR
image; e PET image from
PET/CT; f) PET image from
PET/MR. Evaluation of the nasal
cavity tumour (a , b arrows) and
of the right hilum and carina
(c , d) is concordant. Evaluation
of the left hilum is discordant
(c–f arrows): PET/MR detected
three lymph nodes, which were
interpreted as malignant, and
PET/CT detected only one node
which was interpreted as
malignant. Histology revealed
inflammatory nodes






p value PET/MR PET/CT Difference
(%)
p value
Tumour 32 2.7 [1.8;3.3] 5.5 [4.2;8.7] 7.7 [5.4;11.5] −20.7 <0.01 6.6 [5.3;10.9] 8.7 [7.3;15.1] −24.1 <0.01
Malignant
lymph node
Neck 10 1.2 [0.8;1.4] 2.6 [2.5;5.4] 3.3 [2.9;5.8] −16.3 <0.01 3.9 [3.4;7.3] 4.7 [4.4;8.5] −22.0 <0.01
Mediastinum 13 1.1 [0.6;1.4] 5.4 [4.0;6.6] 4.6 [2.5;6.5] +13.0 0.744 7.4 [5.8;11.3] 7.8 [4.0;9.2] +7.9 0.851
Metastasis 11 1.7 [1.4;2.1] 2.1 [1.3;2.6] 3.0 [1.9;3.4] −12.1 0.43 2.3 [1.6;3.5] 3.7 [2.9;4.4] −17.0 0.34
Benign focal uptake 136 1.2 [0.9;1.8] 2.1 [1.6;2.8] 2.3 [1.8;3.4] −12.7 <0.01 2.6 [2.1;3.6] 3.2 [2.4;4.7] −17.1 <0.01
All lesions 202 1.4 [1.0;2.1] 2.6 [1.7;3.9] 2.8 [1.9;4.5] −13.3 <0.01 3.3 [2.3;5.3] 4.0 [2.7;6.4] −17.4 <0.01
The data are presented as medians and interquartile intervals
aMaximum length in centimetres according to RECIST criteria
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PET/MR compared to those of PET/CT in a clinical setting
using optimized protocols for both systems, as reported re-
cently by other investigators [12, 27]. Study logistics and
timing may also play a role, as SUVs of malignant tumours
may increase over time within a few hours after radiotracer
injection while SUVs of inflammatory lesions tend to decrease
or remain stable [29, 30]. In our study, PET/MR was
performed at a mean of 61 min prior to PET/CT, and SUVs
measured on PET/MR were significantly lower than those on
PET/CT for tumours, metastatic neck nodes and benign focal






p value PET/MR PET/CT Difference
(%)
p value
Lung 61 0.35 [0.30;0.42] 0.31 [0.24;0.38] +11.0 0.03 0.43 [0.36;0.52] 0.44 [0.32;0.54] +0.7 0.90
Muscle 182 0.78 [0.67;0.90] 0.75 [0.62;0.94] +3.0 0.47 1.00 [0.81;1.14] 1.06 [0.86;1.30] −4.6 0.25
Bone marrow 129 1.02 [0.59;1.41] 1.22 [0.67;1.95] −20.0 <0.01 1.44 [0.83;1.87] 1.72 [0.96;2.51] −20.0 <0.01
Salivary glands 37 1.57 [1.38;1.84] 1.56 [1.07;2.10] +11.6 0.22 2.00 [1.62;2.30] 2.11 [1.74;2.75] −4.7 0.49
Spleen 30 1.61 [1.37;1.82] 1.79 [1.46;2.02] −7.8 0.07 2.12 [1.87;2.35] 2.43 [2.20;3.09] −13.4 <0.01
Liver 31 1.75 [1.52;2.05] 1.99 [1.67;2.26] −8.9 0.02 2.35 [2.00;2.68] 2.72 [2.17;3.27] −12.7 <0.01
Background 32 1.05 [0.94;1.14] 1.11 [1.01;1.23] −6.4 0.09 1.37 [1.22;1.50] 1.52 [1.37;1.72] −11.9 <0.01
All 502 0.89 [0.61;1.33] 0.93 [0.59;1.49] −4.8 0.26 1.16 [0.78;1.68] 1.30 [0.85;2.05] −9.7 <0.01
The data are presented as medians and interquartile intervals
Fig. 6 Spearman correlation analysis of tracer uptake for organs (a
SUVmean, b SUVmax) shows strong positive monotonic correlations for
both SUVmean and SUVmax from PET/MR and those from PET/CT.
SUVmean ρ =0.868, n =470, p <0.001; SUVmax ρ =0.872, n =470,
p <0.001. Bland-Altman plots of SUVmean (c ) and SUVmax (d ) for
organs on PET/MR and PET/CT. Differences and limits of agree-
ment (bias±2SD) are expressed as a function of the average
SUVs from PET/MR and from PET/CT. The systematic underes-
timation of SUVs from PET/MR is proportional to the SUV
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uptake (13.3 % mean underestimation for SUVmean and
17.4 % mean underestimation for SUVmax; Tables 5 and 6),
but not for malignant mediastinal nodes or distant metastases,
for which we observed only a trend. This finding can be
partially attributed to the above-mentioned effect of timing,
which is inherent in the design of the study, and tracer kinetics
may thus have been responsible for some of the discrepant
readings observed in the current study. Nevertheless, the ob-
served underestimation of SUVs of benign lesions (mostly of
inflammatory origin), as well as organs on PET/MR as com-
pared to PET/CT (Tables 5 and 6) cannot be explained by
tracer kinetics alone.
In three recent studies in which PET/MR was performed
54, 88 and 92 min after PET/CT, PET/MR underestimated
SUVs for focal lesions and/or organs [12, 27, 31]. In two
studies comparing simultaneous PET/MR and PET/CT in
patients with a mixed spectrum of neoplastic and inflamma-
tory pathologies, Drzezga et al. [12] and Wiesmüller et al.
[27] found that PET/MR underestimated SUV for focal up-
take in a similar range to that found in our study (11 – 12 %
underestimation for SUVmean and 20 % underestimation for
SUVmax), although the two groups used different PET/MR
systems, different study designs and different statistical ap-
proaches [12, 27]. From a statistical point of view, data ob-
tained from PET scans are typically clustered data, and com-
plicatedmodelling techniquesmay be required for correct data
analysis [25, 26]. To avoid bias from multiple lesions per
patient, previous investigators have used conventional statis-
tical tests and limited their analysis to five lesions per organ or
compartment [12, 27]. In our analysis, the lesions were
analysed taking into consideration data clustering [25, 26].
Despite the above-mentioned differences in study design and
data analysis, in accordance with previous authors [12, 27, 32]
we found a statistically significant underestimation of SUVs
measured on PET/MR as compared to those measured on
PET/CT not only for malignant tumours and metastatic neck
nodes but also for benign focal uptake, bonemarrow and liver.
In agreement with previous investigators [12, 27, 32], our
study also demonstrated a statistically significant strong pos-
itive correlation between SUV measurements from PET/MR
Fig. 7 Spearman correlation analysis of tracer uptake for lesions with
focal uptake (tumours, metastatic lymph nodes, metastases and benign
focal uptake; a SUVmean, b SUVmax) shows strong positive monotonic
correlations for both SUVmean and SUVmax from PET/MR and those from
PET/CT. SUVmean ρ =0.872, n =202, p <0.001; SUVmax ρ =0.843,
n =202, p <0.001. Bland-Altman plots of SUVmean (c) and SUVmax (d)
for lesions with focal uptake on PET/MR and PET/CT. Differences and
limits of agreement (bias±2SD) are expressed as a function of the average
SUVs from PET/MR and from PET/CT. The systematic underestimation
of SUVs from PET/MR is proportional to the SUV. Note the dispersion of
the data for SUVmean >10 and SUVmax >12
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and those from PET/CT (Figs. 6 and 7) for benign and
malignant lesions and for organs. However, a significant
nonzero correlation coefficient does not imply that two
methods are concordant [23]. Concordance of measurements
obtained with two different modalities is important in terms of
interchangeable use of measurements performed with either of
the two modalities and in terms of facilitated comparison of
quantitative data from different institutions. Quantification of
tracer uptake plays an increasing relevant role in patients with
head and neck cancer as an increasing number of protocols use
sequential SUV measurements during treatment and in the
early posttreatment phase, for the assessment of treatment
response, to adapt treatment plans individually, and for sys-
tematic follow-up purposes after radio(chemo)therapy [20, 21,
33–35]. In our study, the Bland-Altman plots revealed a
limited concordance of measurements in particular for lesions
with high SUVs (Figs. 6 and 7). In malignant tumours, the
relative difference between SUVs from PET/MR and those
from PET/CTwas influenced, among the factors analysed, by
lesion size (the larger the tumour, the higher the SUV) and the
difference in SUVs, but other factors, such as anatomic loca-
tion and lesion type did not affect the difference between
SUVs measured on PET/MR and those measured on PET/CT.
SUV has been shown to depend on tumour size, partial
volume effect, data acquisition, reconstruction protocol and
image characteristics (spatial resolution, noise, number of
iterations and attenuation correction method) [36–38]. The
attenuation correction method used in PET/MR ignores the
presence of bony structures in contrast to that used in PET/CT.
Some investigators have suggested that ignoring bone could
be acceptable for the abdominal and hip regions [18, 39] but
probably not in the thorax or in the head and neck [40]. Bini
et al. [32] recently showed in an animal model that the MR
attenuation correction method underestimated PET values by
less than 10% inmost regions except areas containing bone or
areas close to large bony structures. Ignoring bone might also
not be adequate for quantification of osseous lesions with a
reported difference between measurements on PET/MR and
PET/CT of 5 – 30 % [18, 40, 41].
From a clinical point of view, our study suggests that SUVs
measured on PET/MR and those measured on PET/CT may
differ in particular in large head and neck tumours (Fig. 7).
Although this finding may not be relevant for qualitative
interpretation of PET scans for diagnostic purposes, it may
have implications for tracer quantification. Therefore, when
monitoring response to chemo(radio)therapy and for follow-
up purposes in patients with head and neck oncology, if the
initial examination was a PET/MR scan, particular care should
be taken to perform the follow-up examinations on the same
PET/MR machine in order to allow better evaluation of quan-
titative changes in tracer uptake, and vice-versa, the informa-
tion that SUVs of head and neck tumours may be
underestimated by 20 % using PET/MR as compared to
PETR/CT may be important for the every-day clinical use of
this new hybrid technology.
Conclusion
In this study, we showed that in patients with head and neck
oncology, the PET data obtained with a sequential PET/MR
show equivalent findings to the PET data from PET/CT
regarding image and fusion quality, lesion conspicuity, ana-
tomic location of focal uptake, number of detected malignant
and benign lesions and number of diagnosed patients with and
without malignant lesions. Comparison of SUVs revealed an
excellent correlation for measurements on bothmodalities, but
underestimation of 18F-FDG uptake for focal lesions (benign
and malignant) and organs as compared to that estimated from
PET/CT. Among the tested factors, tumour size was the major
factor affecting the difference between SUV measured on
PET/MR and those measured on PET/CT.
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